Start-ups and spin-outs in Life Sciences
We have a successful record in launching spin-out companies which has helped drive the establishment of a life sciences cluster which makes a major contribution to the Tay Cities regional economy.
Developing drugs using ground-breaking targeted protein degradation technology from the laboratory of Professor Alessio Ciulli. Amphista was named one of 2022’s Fierce 15 biotechnology companies.
In 2022, they announced collaborations with Merck Healthcare and Bristol Myers Squibb potentially worth $2 billion. It won ‘Deal of the Year >€500m' category at the Lifestars Awards for those simultaneously announced deals.
Exscientia develops and applies pioneering artificial intelligence (AI) drug design methodologies that enhance the efficacy and the efficiency of drug discovery for the pharmaceutical industry.
Exscientia collaborates with leading pharmaceutical companies and underwent Europe’s largest IPO on the NASDAQ in 2021. With a market capitalisation of over $2Bn, it is now one of the UK’s largest Biotech companies.
Specialises in developing new therapeutics for unmet medical needs. They target defined patient subgroups with differentiated small molecule therapeutics. They are currently developing their next pipeline assets by targeting stop codon mutations in cancer and genetic diseases.
In 2023, they announced a licensing deal to VYNE Therapeutics for an inhibitor for immuno-inflammatory and fibrotic disorders potentially worth $50m in upfront and milestones plus mid-tier single digit royalties.
Ten Bio Ltd
An exciting new biotech spin out company offering innovative human skin explant technology that allows superior retention of in vivo physiological characteristics for testing of pharmaceuticals and cosmetics products, reducing the need for testing in animal models.
In 2021, they announced near £1 million investment from TRICAPITAL LTD and Scottish Enterprise.